212 related articles for article (PubMed ID: 12917237)
1. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
2. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio.
Lincopan N; Borelli P; Fock R; Mamizuka EM; Carmona-Ribeiro AM
Exp Toxicol Pathol; 2006 Nov; 58(2-3):175-83. PubMed ID: 16982179
[TBL] [Abstract][Full Text] [Related]
4. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
5. Lipid-covered drug particles: combined action of dioctadecyldimethylammonium bromide and amphotericin B or miconazole.
Lincopan N; Carmona-Ribeiro AM
J Antimicrob Chemother; 2006 Jul; 58(1):66-75. PubMed ID: 16636081
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of the interaction of the polyene antibiotic Amphotericin B with DODAB bicelles and vesicles.
Oliveira TR; Benatti CR; Lamy MT
Biochim Biophys Acta; 2011 Nov; 1808(11):2629-37. PubMed ID: 21839723
[TBL] [Abstract][Full Text] [Related]
7. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
10. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
11. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice.
Shadkchan Y; Segal E
J Antimicrob Chemother; 1999 Dec; 44(6):787-90. PubMed ID: 10590279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.
Santangelo R; Paderu P; Delmas G; Chen ZW; Mannino R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2000 Sep; 44(9):2356-60. PubMed ID: 10952579
[TBL] [Abstract][Full Text] [Related]
14. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
15. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
17. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
[TBL] [Abstract][Full Text] [Related]
19. Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model.
Grisin T; Bories C; Bombardi M; Loiseau PM; Rouffiac V; Solgadi A; Mallet JM; Ponchel G; Bouchemal K
Pharm Res; 2017 May; 34(5):1067-1082. PubMed ID: 28168390
[TBL] [Abstract][Full Text] [Related]
20. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency.
Burgess BL; He Y; Baker MM; Luo B; Carroll SF; Forte TM; Oda MN
Int J Nanomedicine; 2013; 8():4733-43. PubMed ID: 24379661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
